Adverse Drug Reactions in Patients on Second Line Anti-Tubercular Drugs for Drug Resistant Tuberculosis in Rural Tertiary Care Hospital in North India

Kumari, Anita; Sharma, Parveen; Kansal, Dinesh; Bansal, Rekha; Negi, Rajan

doi:10.4236/jtr.2018.63019

Cited by 3 publications

(3 citation statements)

References 3 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, vomiting was the most frequently reported ADR, followed by arthralgia, nausea, neuropathy peripheral, and prolongation of electrocardiogram QT, a finding that is more or less similar to the findings from previous studies [20,[26][27][28]. The same sets of ADRs were also reported in a four-year retrospective study conducted by Arif et al [29].…”

Section: Adverse Drug Reactionssupporting

confidence: 91%

Safety Profile of Medicines Used for the Treatment of Drug-Resistant Tuberculosis: A Descriptive Study Based on the WHO Database (VigiBase®)

et al. 2023

View full text Add to dashboard Cite

Background: The introduction of new drugs that increase the usage of repurposed medicines for managing drug-resistant tuberculosis (DR-TB) comes with challenges of understanding, properly managing, and predicting adverse drug reactions (ADRs). In addition to the health consequences of ADRs for the individual, ADRs can reduce treatment adherence, thus contributing to resistance. This study aimed to describe the magnitude and characteristics of DR-TB-related ADRs through an analysis of ADRs reported to the WHO database (VigiBase) in the period from January 2018 to December 2020. Methods: A descriptive analysis was performed on selected reports from VigiBase on the basis of medicine-potential ADR pairs. The ADRs were stratified by sex, age group, reporting country, seriousness, outcome of the reaction, and dechallenge and rechallenge. Results: In total, 25 medicines reported to be suspected individual medicines or as a fixed-dose combination in the study period were included the study. Pyrazinamide (n = 836; 11.2%) was the most commonly reported medicine associated with ADRs, followed by ethionamide (n = 783; 10.5%) and cycloserine (n = 696; 9.3%). From the report included in this analysis, 2334 (31.2%) required complete withdrawal of the suspected medicine(s), followed by reduction of the dose (77; 1.0%) and an increased dose (4; 0.1%). Almost half of the reports were serious ADRs mainly caused by bedaquiline, delamanid, clofazimine, linezolid, and cycloserine that are the backbone of the DR-TB treatment currently in use. Conclusions: A third of the reports required medication withdrawal, which impacts treatment adherence and ultimately leads to drug resistance. Additionally, more than 40% of the reports indicated that ADRs appeared two months after the commencement of treatment, thus it’s important to remain alert for the potential ADRs for the entire duration of the treatment.

show abstract

Section: Adverse Drug Reactionssupporting

confidence: 91%

Safety Profile of Medicines Used for the Treatment of Drug-Resistant Tuberculosis: A Descriptive Study Based on the WHO Database (VigiBase®)

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Similar to present study Kumari et al suggested that majority of ADRs' onset within 2 -3 months of initiation of treatment. 15 Better counselling and surveillance could be the reason behind early detection of ADRs. Therefore it is responsibility of health care professional to counsel and guide the patient regarding the early signs of ADRs.…”

Section: Discussionmentioning

confidence: 99%

An observational study of adverse drug reactions in hospitalized patients of drug resistance tuberculosis taking PMDT therapy in a tertiary care hospital

Naik¹,

Pandey²,

Patel³

2021

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Background: Drug resistant tuberculosis is an important public health issue in India. The treatment regimen followed is Programmatic Management of Drug resistant Tuberculosis (PMDT) approach. Adverse drug reactions (ADRs) are a serious issue which increases the risk of defaulter rate if poorly managed. Thus study was undertaken to assess the ADRs caused by PMDT therapy in indoor patients of Department of Respiratory Medicine in a tertiary care hospital at Surat.Methods: The prospective and observational study was carried out for one year period. The causality was determined by World Health Organization (WHO) Uppasala Monitoring Centre (UMC) scale and severity was determined by Modified Hartwig and Siegel scale. Fisher exact test was applied for statistical analysis.Results: Among 24 drug resistant tuberculosis patients, 12 (50%) patients developed ADRs due to second line antitubercular drugs. Occurrence of ADRs was more among Category V (100%) as compared to Category IV (36.8%). Occurrence of ADRs was more among females (60%). The commonly involved systems are auditory system (33.3%). Majority of ADRs developed within 61-90 days (66.7%) of initiation of drug therapy. Highest percentage of ADRs causing drugs was pyrazinamide (27.8%). On evaluation of the causality of ADRs, majority were found to be possible (53.3%). The severity assessment showed that most of the patients ADRs were of moderate level (73.3%).Conclusions: PMDT therapy is complicated but early management and reporting of ADRs decreases default rate.

show abstract

“…Treatment for drug-resistant tuberculosis is frequently more hazardous and difficult, resulting in fewer treatment outcomes, such as treatment failure or death, and a longer treatment period. In areas with limited resources, it is essential to closely monitor drug-resistant tuberculosis therapy, identify prognostic predictive indicators early, and closely monitor body weight to ensure medication success [10].…”

Section: Introductionmentioning

confidence: 99%

A Review Study on Safety and Efficacy on Second Line Anti Tubercular Drugs

Sreelatha,

Naveena,

Chandra

2023

Int. J.Exp. Biomed. Res.

View full text Add to dashboard Cite

Due to intestinal dysbiosis brought on by second-line anti-tubercular medication therapy, the patient's resistance to MTB appears to have decreased. This is likely due to an impact on immune cell proliferation and autophagic processes. therefore adversely influencing the patients' treatment results. The objectives of review articles are the safety and efficacy on the second line anti tubercular drugs. The results of these review article in the year 2015 to 2020. The conversation of these review article is the safety and efficacy of second line anti tubercular drugs . The discussion of these study about the safety and efficacy on second line anti tubercular drugs . 2016 levofloxacin is a not more safe and less effective because result insufficient control to the tuberculosis patient it adverse events is underactive thyroid. 2020 Ethionamide is a safe and effective for the TB patients. The conclusion of these review study and efficacy of the second line anti tubercular drugs. The ofloxacin are the most effective and safe when compared to the other second line anti tubercular drugs. In second line anti tubercular drugs the levofloxacin is having the less efficacy when compared to other second line anti tubercular drugs because it is having the adverse effect of the hypothyroidism. For the treatment of tuberculosis the drugs used are the levofloxacin, kanamycin, etc and these are most commonly used for the prevention of the disease.

show abstract

Adverse Drug Reactions in Patients on Second Line Anti-Tubercular Drugs for Drug Resistant Tuberculosis in Rural Tertiary Care Hospital in North India

Cited by 3 publications

References 3 publications

Safety Profile of Medicines Used for the Treatment of Drug-Resistant Tuberculosis: A Descriptive Study Based on the WHO Database (VigiBase®)

Safety Profile of Medicines Used for the Treatment of Drug-Resistant Tuberculosis: A Descriptive Study Based on the WHO Database (VigiBase®)

An observational study of adverse drug reactions in hospitalized patients of drug resistance tuberculosis taking PMDT therapy in a tertiary care hospital

A Review Study on Safety and Efficacy on Second Line Anti Tubercular Drugs

Contact Info

Product

Resources

About